Further, BAT, which is working in conjunction with its U.S. biotech subsidiary, Kentucky BioProcessing (KBP), stated that if testing goes well, and “with the right partners and support from government agencies,” they could potentially begin manufacturing the experimental vaccine in June 2020.



Read more…